Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Moleculin Biotech Inc. (MBRX:NASDAQ), powered by AI.
Moleculin Biotech Inc. is currently trading at $2.70. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Moleculin Biotech Inc. on Alpha Lenz.
View Moleculin Biotech Inc.'s valuation metrics on Alpha Lenz.
“Moleculin Biotech Inc.'s ROE is -319.8%. Explore profitability and growth together.”
Ask for details →Moleculin Biotech Inc. is a clinical-stage pharmaceutical company that primarily focuses on the development of oncology drug candidates. Based in Houston, Texas, the company concentrates its efforts on addressing unmet medical needs related to cancer. Moleculin Biotech is notable for its diverse pipeline of drug candidates, which includes small molecules targeting key biological pathways involved in cancer cell proliferation and survival. The company leverages its novel technologies, such as its Immune/Transcription Modulary Technology, to develop potential treatments that can be more effective and less toxic than existing therapies. Moleculin Biotech's research and developments are particularly influential within the biotechnology and pharmaceutical sectors, contributing to advancements in cancer treatment and offering hope for new therapeutic options. Through its innovative approach to drug development, Moleculin Biotech Inc. plays a significant role in the broader scientific and medical community, aiming to translate groundbreaking research into practical treatments that can improve patient outcomes.
“Moleculin Biotech Inc.'s ROE is -319.8%. Explore profitability and growth together.”
Ask for details →Moleculin Biotech Inc. (ticker: MBRX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 17 employees.
The current price is $2.7 with a P/E ratio of -x and P/B of -x.
ROE is -319.85%.